{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:15:49Z","timestamp":1792696549446,"version":"4.5.0"},"reference-count":66,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2015,3,12]],"date-time":"2015-03-12T00:00:00Z","timestamp":1426118400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JoF"],"abstract":"<jats:p>Background: Pityriasis versicolor (PV), also known as tinea versicolor, is caused by Malassezia species. This condition is one of the most common superficial fungal infections worldwide, particularly in tropical climates. PV is difficult to cure and the chances for relapse or recurrent infections are high due to the presence of Malassezia in the normal skin flora. This review focuses on the clinical evidence supporting the efficacy of antifungal treatment for PV. Method: A systematic review of literature from the PubMed database was conducted up to 30 September 2014. The search criteria were \u201c(pityriasis versicolor OR tinea versicolor) AND treatment\u201d, with full text available and English language required. Conclusions: Topical antifungal medications are the first-line treatment for PV, including zinc pyrithione, ketoconazole, and terbinafine. In cases of severe or recalcitrant PV, the oral antifungal medications itraconazole and fluconazole may be more appropriate, with pramiconazole a possible future option. Oral terbinafine is not effective in treating PV and oral ketoconazole should no longer be prescribed. Maintenance, or prophylactic, therapy may be useful in preventing recurrent infection; however, at this time, there is limited research evaluating the efficacy of prophylactic antifungal treatment.<\/jats:p>","DOI":"10.3390\/jof1010013","type":"journal-article","created":{"date-parts":[[2015,3,12]],"date-time":"2015-03-12T11:30:24Z","timestamp":1426159824000},"page":"13-29","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":65,"title":["Antifungal Treatment for Pityriasis Versicolor"],"prefix":"10.3390","volume":"1","author":[{"given":"Aditya","family":"Gupta","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Toronto, Toronto, ON M5G 2C4, Canada"},{"name":"Mediprobe Research Inc., London, ON N5X 2P1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Foley","sequence":"additional","affiliation":[{"name":"Mediprobe Research Inc., London, ON N5X 2P1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2015,3,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/0190-9622(91)70198-B","article-title":"Tinea versicolor: Epidemiologic, clinical, and therapeutic aspects","volume":"25","author":"Borelli","year":"1991","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1046\/j.1468-3083.2002.00378.x","article-title":"Pityriasis versicolor","volume":"16","author":"Gupta","year":"2002","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/01.qco.0000216624.21069.61","article-title":"Malassezia yeasts and pityriasis versicolor","volume":"19","author":"Florencio","year":"2006","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1034\/j.1398-9995.1999.00089.x","article-title":"Pityrosporum species as a cause of allergy and infection","volume":"54","author":"Faergemann","year":"1999","journal-title":"Allergy"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/09546630410032421","article-title":"Treatment of pityriasis versicolor in the United States","volume":"15","author":"Mellen","year":"2004","journal-title":"J. Dermatol. Treat."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1046\/j.1525-1470.2000.01715.x","article-title":"Diagnosing tinea versicolor: Don\u2019t scrape, just tape","volume":"17","author":"Rogers","year":"2000","journal-title":"Pediatr. Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"12","DOI":"10.2340\/00015555-1825","article-title":"Evidence-based Danish Guidelines for the Treatment of Malassezia-related Skin Diseases","volume":"95","author":"Hald","year":"2015","journal-title":"Acta Derm. Venereol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0733-8635(03)00039-1","article-title":"Pityriasis versicolor","volume":"21","author":"Gupta","year":"2003","journal-title":"Dermatol. Clin."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1517\/14656566.6.2.165","article-title":"Pityriasis versicolor: A review of pharmacological treatment options","volume":"6","author":"Gupta","year":"2005","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/j.1439-0507.1991.tb00676.x","article-title":"Clinical efficacy and tolerability of terbinafine in patients with pityriasis versicolor","volume":"34","author":"Aste","year":"1991","journal-title":"Mycoses"},{"key":"ref_11","first-page":"86","article-title":"Comparative study of ketoconazole versus selenium sulphide shampoo in pityriasis versicolor","volume":"69","author":"Aggarwal","year":"2003","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"key":"ref_12","first-page":"298","article-title":"A double-blind comparison of 2% ketoconazole and 1% clotrimazole in the treatment of pityriasis versicolor","volume":"62","author":"Balwada","year":"1996","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/j.1346-8138.2010.00908.x","article-title":"Single-dose oral fluconazole versus topical clotrimazole in patients with pityriasis versicolor: A double-blind randomized controlled trial","volume":"37","author":"Dehghan","year":"2010","journal-title":"J. Dermatol."},{"key":"ref_14","first-page":"574","article-title":"Treatment of tinea versicolor with a new antifungal agent, ciclopirox olamine cream 1%","volume":"7","author":"Cullen","year":"1985","journal-title":"Clin. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/S0190-9622(86)70200-4","article-title":"Double-blind comparison of 2% ketoconazole cream and placebo in the treatment of tinea versicolor","volume":"15","author":"Savin","year":"1986","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_16","first-page":"299","article-title":"Comparative study of topical terbinafine and topical ketoconazole in pityriasis versicolor","volume":"66","author":"Chopra","year":"2000","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/S0190-9622(98)70267-1","article-title":"Ketoconazole 2% shampoo in the treatment of tinea versicolor: A multicenter, randomized, double-blind, placebo-controlled trial","volume":"39","author":"Lange","year":"1998","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_18","first-page":"142","article-title":"Ketoconazole 2% shampoo in pityriasis versicolor: An open trial","volume":"69","author":"Rathi","year":"2003","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1439-0507.2006.01352.x","article-title":"Flutrimazole shampoo 1% versus ketoconazole shampoo 2% in the treatment of pityriasis versicolor. A randomised double-blind comparative trial","volume":"50","author":"Rigopoulos","year":"2007","journal-title":"Mycoses"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/j.1439-0507.2008.01508.x","article-title":"Comparative efficacy and tolerability of Ketomousse (ketoconazole foam 1%) and ketoconazole cream 2% in the treatment of pityriasis versicolor: Results of a prospective, multicentre, randomised study","volume":"51","author":"Martini","year":"2008","journal-title":"Mycoses"},{"key":"ref_21","first-page":"855","article-title":"Can pityriasis versicolor be treated with 2% ketoconazole foam?","volume":"13","author":"Cantrell","year":"2014","journal-title":"J. Drugs Dermatol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Shi, T.W., Zhang, J.A., Tang, Y.B., Yu, H.X., Li, Z.G., and Yu, J.B. (2014). A randomized controlled trial of combination treatment with ketoconazole 2% cream and adapalene 0.1% gel in pityriasis versicolor. J. Dermatol. Treat.","DOI":"10.3109\/09546634.2014.921661"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1365-2230.1989.tb00905.x","article-title":"Clinical efficacy of terbinafine in 629 Japanese patients with dermatomycosis","volume":"14","author":"Kagawa","year":"1989","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1159\/000246178","article-title":"Pityriasis versicolor: Clinical experience with Lamisil cream and Lamisil DermGel","volume":"194","author":"Faergemann","year":"1997","journal-title":"Dermatology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1159\/000246179","article-title":"The efficacy of a topical application of terbinafine 1% solution in subjects with pityriasis versicolor: A placebo-controlled study","volume":"194","author":"Vermeer","year":"1997","journal-title":"Dermatology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1046\/j.1365-4362.1999.00730.x","article-title":"Tinea versicolor treated with terbinafine 1% solution","volume":"38","author":"Savin","year":"1999","journal-title":"Int. J. Dermatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1080\/09546630252775243","article-title":"One-week terbinafine 1% solution in pityriasis versicolor: Twice-daily application is more effective than once-daily","volume":"13","author":"Budimulja","year":"2002","journal-title":"J. Dermatol. Treat."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/S0190-9622(09)80305-8","article-title":"Mechanisms of action of systemic antifungal agents","volume":"28","author":"Elewski","year":"1993","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.2165\/00003495-200464130-00005","article-title":"Adapalene: A review of its use in the treatment of acne vulgaris","volume":"64","author":"Waugh","year":"2004","journal-title":"Drugs"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1159\/000338198","article-title":"Roles of adapalene in the treatment of pityriasis versicolor","volume":"224","author":"Shi","year":"2012","journal-title":"Dermatology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1365-2230.1989.tb00901.x","article-title":"In vitro activity of terbinafine","volume":"14","author":"Clayton","year":"1989","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1365-2133.1992.tb00001.x","article-title":"Terbinafine: Mode of action and properties of the squalene epoxidase inhibition","volume":"126","author":"Ryder","year":"1992","journal-title":"Br. J. Dermatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/j.1365-2230.1989.tb00908.x","article-title":"Clinical efficacy and tolerability of terbinafine (Lamisil)\u2014A new topical and systemic fungicidal drug for treatment of dermatomycoses","volume":"14","author":"Villars","year":"1989","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1365-2133.1992.tb00013.x","article-title":"Special features of the clinical use of oral terbinafine in the treatment of fungal diseases","volume":"126","author":"Villars","year":"1992","journal-title":"Br. J. Dermatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1365-2230.1994.tb01138.x","article-title":"Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once daily for 7 and 14 days","volume":"19","author":"Faergemann","year":"1994","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1046\/j.1365-2125.1999.00095.x","article-title":"A cohort study on the risk of acute liver injury among users of ketoconazole and other antifungal drugs","volume":"48","author":"Duque","year":"1999","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_37","first-page":"605","article-title":"Ketoconazole associated hepatotoxicity: A systematic review and meta- analysis","volume":"26","author":"Yan","year":"2013","journal-title":"Biomed. Environ. Sci."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1517\/14740338.2015.983071","article-title":"Drug safety assessment of oral formulations of ketoconazole","volume":"14","author":"Gupta","year":"2015","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_39","unstructured":"U.S. Food and Drug Administration FDA Drug Safety Communication: FDA Limits Usage of Nizoral (ketoconazole) Oral Tablets Due to Potentially Fatal Liver Injury and Risk of Drug Interactions and Adrenal Gland Problems. Available online: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm362415.htm."},{"key":"ref_40","unstructured":"Health Canada Health Canada Endorsed Important Safety Information on Ketoconazole. Ketoconazole\u2014Risk of Potentially Fatal Liver Toxicity\u2014For Health Professionals. Available online: http:\/\/healthycanadians.gc.ca\/recall-alert-rappel-avis\/hc-sc\/2013\/34173a-eng.php."},{"key":"ref_41","unstructured":"European Medicines Agency European Medicines Agency Recommends Suspension of Marketing Authorisations for Oral Ketoconazole. Available online: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Press_release\/2013\/07\/WC500146613.pdf."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/095466302317584421","article-title":"Fluconazole versus ketoconazole in the treatment of tinea versicolor","volume":"13","author":"Farschian","year":"2002","journal-title":"J. Dermatol. Treat."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3109\/09546639909055906","article-title":"Itraconazole versus ketoconazole in the treatment of tinea versicolor","volume":"10","author":"Shemer","year":"1999","journal-title":"J. Dermatol. Treat."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1439-0507.2007.01361.x","article-title":"Comparison between fluconazole and ketoconazole effectivity in the treatment of pityriasis versicolor","volume":"50","author":"Yazdanpanah","year":"2007","journal-title":"Mycoses"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1346-8138.2001.tb00026.x","article-title":"Comparative efficacy of ketoconazole and fluconazole in the treatment of pityriasis versicolor: A one year follow-up study","volume":"28","author":"Bhogal","year":"2001","journal-title":"J. Dermatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"S134","DOI":"10.1093\/clinids\/9.Supplement_1.S134","article-title":"Itraconazole in Pityriasis Versicolor: Ultrastructural Changes in Malassezia furfur Produced during Treatment","volume":"9","author":"Galimberti","year":"1987","journal-title":"Rev. Infect. Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"S131","DOI":"10.1093\/clinids\/9.Supplement_1.S131","article-title":"Pityriasis versicolor: Efficacy of two five-day regimens of itraconazole","volume":"9","year":"1987","journal-title":"Rev. Infect. Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S0190-9622(96)90014-6","article-title":"A double-blind, randomized, placebo-controlled evaluation of short-term treatment with oral itraconazole in patients with tinea versicolor","volume":"34","author":"Hickman","year":"1996","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_49","first-page":"151","article-title":"Single dose itraconazole therapy in tinea versicolor; a double blind, randomised placebo controlled study","volume":"65","author":"Ravikumar","year":"1999","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1080\/09546630212345676","article-title":"Efficacy of three short-term regimens of itraconazole in the treatment of pityriasis versicolor","volume":"13","author":"Kokturk","year":"2002","journal-title":"J. Dermatol. Treat."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1080\/095466302317584430","article-title":"Comparison of a single 400 mg dose versus a 7-day 200 mg daily dose of itraconazole in the treatment of tinea versicolor","volume":"13","author":"Kose","year":"2002","journal-title":"J. Dermatol. Treat."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/archderm.138.1.69","article-title":"Efficacy of itraconazole in the prophylactic treatment of pityriasis (tinea) versicolor","volume":"138","author":"Faergemann","year":"2002","journal-title":"Arch. Dermatol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/j.1365-4362.1995.tb00623.x","article-title":"Fluconazole versus itraconazole in the treatment of tinea versicolor","volume":"34","author":"Kose","year":"1995","journal-title":"Int. J. Dermatol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1046\/j.1365-4362.1997.00213.x","article-title":"Fluconazole in the treatment of tinea versicolor","volume":"36","author":"Amer","year":"1997","journal-title":"Int. J. Dermatol."},{"key":"ref_55","first-page":"166","article-title":"Oral fluconazole in tinea versicolor","volume":"63","author":"Sankara","year":"1997","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"key":"ref_56","first-page":"20","article-title":"Comparative evaluation of single dose regimen with two dose regimen of fluconazole in the treatment of tinea versicolor: A double blind placebo controlled study","volume":"65","author":"Balachandran","year":"1999","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1046\/j.1365-4362.1999.00733.x","article-title":"Fluconazole vs. itraconazole in the treatment of tinea versicolor","volume":"38","author":"Robles","year":"1999","journal-title":"Int. J. Dermatol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000075047","article-title":"Single-dose fluconazole versus itraconazole in pityriasis versicolor","volume":"208","author":"Partap","year":"2004","journal-title":"Dermatology"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1346-8138.2005.tb00707.x","article-title":"Oral fluconazole in the treatment of tinea versicolor","volume":"32","author":"Durdu","year":"2005","journal-title":"J. Dermatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1111\/j.1365-2133.2007.07888.x","article-title":"The efficacy of oral treatment with pramiconazole in pityriasis versicolor: A phase II a trial","volume":"156","author":"Faergemann","year":"2007","journal-title":"Br. J. Dermatol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.jaad.2008.08.033","article-title":"Double-blind, randomized, placebo-controlled, dose-finding study of oral pramiconazole in the treatment of pityriasis versicolor","volume":"61","author":"Faergemann","year":"2009","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"S146","DOI":"10.1093\/clinids\/9.Supplement_1.S146","article-title":"Itraconazole in the Treatment of Human Mycoses: Review of Three Years of Clinical Experience","volume":"9","author":"Cauwenbergh","year":"1987","journal-title":"Clin. Infect. Dis."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2310\/7750.2013.13062","article-title":"Systematic review of systemic treatments for tinea versicolor and evidence-based dosing regimen recommendations","volume":"18","author":"Gupta","year":"2014","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1128\/AAC.48.2.388-391.2004","article-title":"In vitro and in vivo activities of the novel azole antifungal agent r126638","volume":"48","author":"Odds","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/archdermatol.2010.259","article-title":"Pityriasis versicolor: A systematic review of interventions","volume":"146","author":"Hu","year":"2010","journal-title":"Arch. Dermatol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"476","DOI":"10.2340\/0001555551476478","article-title":"Selenium sulphide treatment of tinea versicolor","volume":"51","author":"Hersle","year":"1971","journal-title":"Acta Derm. Venereol."}],"container-title":["Journal of Fungi"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2309-608X\/1\/1\/13\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T20:43:26Z","timestamp":1760215406000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2309-608X\/1\/1\/13"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,12]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,6]]}},"alternative-id":["jof1010013"],"URL":"https:\/\/doi.org\/10.3390\/jof1010013","relation":{},"ISSN":["2309-608X"],"issn-type":[{"value":"2309-608X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,12]]}}}